Comparison Bupropion with srtraline on the depression in Parkinson

Comparison of the effect of Bupropion with sertraline on the treatment of depression in Parkinson patients.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200513047429N1

Enrollment

Registered

2020-06-28

Start date

2020-06-09

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Parkinson. Other depressive episodes Parkinson's disease

Interventions

Intervention 1: Intervention group 1: Depressed Parkinson's patients will be prescribed Bupropion tablets at an initial dose of 75 mg daily, and if there is no initial response after one month, the do

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Parkinson's patients with major depression,

Exclusion criteria

Exclusion criteria: Absence history of other major neurological disorders, such as epilepsy, head trauma, vascular disorders, stroke and dementia, and other major psychiatric disorders, including bipolar disorder, schizophrenia, substance abuse, and use of Antipsychotics in the last 6 months

Design outcomes

Primary

Measure	Time frame
Severity of depression based on Beck's questionnaire. Timepoint: Measuring depression before intervention and then 1 and 3 month after intervention. Method of measurement: Beck's depression questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFayazi Ashraf

Tehran University of Medical Sciences

tums_edu@tums.ac.ir+98 21 6649 2271

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026